Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second...

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD)

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile...

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD) A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S.Topline data for the primary endpoint is expected in Q1 2023 with full trial...